share_log

藥明康德：海外監管公告

WUXI APPTEC: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Mar 18 10:32
Summary by Moomoo AI
药明康德（股份代號：2359）於2024年3月18日發布海外監管公告，公告中提及公司董事會對在任独立董事的独立性進行了評估。評估對象包括独立董事卢韶华、俞卫、张新、詹智玲及冯岱。經過核查独立董事的任职履历及自查報告，確認他們未在公司擔任除独立董事、董事会专门委员会委员以外的任何职务，且與公司及其實際控制人之間不存在利害關係或其他可能影響其独立客观判断的關係。根據《上市公司独立董事管理办法》及《上海证券交易所上市公司自律监管指引第1号——规范运作》等法律法规，公司董事會確認所有在任独立董事均符合相關独立性要求。
药明康德（股份代號：2359）於2024年3月18日發布海外監管公告，公告中提及公司董事會對在任独立董事的独立性進行了評估。評估對象包括独立董事卢韶华、俞卫、张新、詹智玲及冯岱。經過核查独立董事的任职履历及自查報告，確認他們未在公司擔任除独立董事、董事会专门委员会委员以外的任何职务，且與公司及其實際控制人之間不存在利害關係或其他可能影響其独立客观判断的關係。根據《上市公司独立董事管理办法》及《上海证券交易所上市公司自律监管指引第1号——规范运作》等法律法规，公司董事會確認所有在任独立董事均符合相關独立性要求。
Ming Kand Pharmaceuticals (Stock Code: 2359) issued an Overseas Regulatory Notice on 18 March 2024, mentioning that the Company's Board of Directors has assessed the independence of independent directors. The evaluators included the independent directors Lu Shaohua, Yu Wei, Zhang Xin, Zhan Zhi Ling and Feng Dai. A review of the independent directors' resumes and self-examination reports confirms that they have not held any positions in the company other than as an independent director, a member of a special committee of the Board of Directors, and that there is no interest or other relationship between the company and its actual controller or other relationship that may affect its independent objective judgment. Pursuant to legal regulations such as the Ordinance on the Management of Independent Directors of Listed Companies and the Code of Conduct on Self-Governance of Listed Companies No. 1 - Standard Operations, the Board of Directors of the Company confirms that all acting independent directors comply with the relevant independence requirements.
Ming Kand Pharmaceuticals (Stock Code: 2359) issued an Overseas Regulatory Notice on 18 March 2024, mentioning that the Company's Board of Directors has assessed the independence of independent directors. The evaluators included the independent directors Lu Shaohua, Yu Wei, Zhang Xin, Zhan Zhi Ling and Feng Dai. A review of the independent directors' resumes and self-examination reports confirms that they have not held any positions in the company other than as an independent director, a member of a special committee of the Board of Directors, and that there is no interest or other relationship between the company and its actual controller or other relationship that may affect its independent objective judgment. Pursuant to legal regulations such as the Ordinance on the Management of Independent Directors of Listed Companies and the Code of Conduct on Self-Governance of Listed Companies No. 1 - Standard Operations, the Board of Directors of the Company confirms that all acting independent directors comply with the relevant independence requirements.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more